Investing.com – Germany stocks were mixed after the close on Tuesday, as gains in the Consumer & Cyclical, Telecoms and Pharmaceuticals & Healthcare sectors led shares higher while...
Investing.com – Germany stocks were higher after the close on Monday, as gains in the Technology, Consumer & Cyclical and Industrials sectors led shares higher. At the close in...
Investing.com – Germany stocks were higher after the close on Thursday, as gains in the Retail, Pharmaceuticals & Healthcare and Industrials sectors led shares higher. At the...
Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 361.44 | 362.30 | 357.00 | +2.52 | +0.70% | 3.98M | NASDAQ | |||
| 2,717.30 | 2,720.10 | 2,698.40 | +14.8 | +0.55% | 271.30K | NASDAQ | |||
| 63.44 | 66.50 | 58.31 | -6.95 | -9.87% | 32.61M | NASDAQ | |||
| 205.72 | 207.30 | 203.45 | +2.98 | +1.47% | 8.54M | NASDAQ | |||
| 589.15 | 594.10 | 571.43 | +8.20 | +1.41% | 397.03K | NASDAQ | |||
| 200.45 | 218.22 | 199.71 | -31.03 | -13.40% | 3.17M | NYSE | |||
| 199.79 | 200.29 | 197.64 | -0.92 | -0.46% | 3.77M | NYSE | |||
| 186.57 | 190.39 | 175.00 | -15.53 | -7.68% | 5.80M | NASDAQ | |||
| 31.94 | 32.59 | 28.91 | +2.10 | +7.04% | 41.27M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 14.21 | 14.92 | 9.95 | +5.96 | +72.24% | 49.38M | NASDAQ | |||
| 19.68 | 19.69 | 19.24 | +0.62 | +3.25% | 2.22M | NYSE | |||
| 245.55 | 246.50 | 237.73 | +1.19 | +0.49% | 1.15M | NASDAQ | |||
| 152.20 | 153.49 | 145.22 | +5.40 | +3.68% | 931.44K | NYSE | |||
| 6.40 | 6.48 | 6.33 | -0.090 | -1.39% | 2.34M | NYSE |
Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company’s EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company’s portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women’s health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.
